Therapeutic Drug Monitoring Market by Product, Technology, Drug Class, End-User

Description

List of Tables

[196 Pages Report] The Therapeutic Drug Monitoring Market size was estimated at USD 3.79 billion in 2023 and expected to reach USD 4.38 billion in 2024, at a CAGR 16.11% to reach USD 10.78 billion by 2030.

Therapeutic drug monitoring is the clinical testing process of measuring plasma, serum, or blood drug concentrations. These therapeutic drug monitoring processes enable designing the patient-specific dosage regimen, optimizing the effectiveness of drugs, and maintaining a certain level of drug substance in patients' bodies. The increase in chronic disease incidences and growth in the healthcare and pharmaceutical industries create the need for therapeutic drug monitoring to monitor drug dosage safety and efficacy effectively. However, the limited availability of skilled laboratory technicians and inadequate reimbursement policies is hampering the growth of the market. Furthermore, the developments in immunoassay and other therapeutic drug monitoring technologies are creating opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023]	USD 3.79 billion
Estimated Year [2024]	USD 4.38 billion
Forecast Year [2030]	USD 10.78 billion
CAGR (%)	16.11%

Product: Rising demand for data management services for efficient drug management

Consumables include indispensable disposable items such as reagents, kits, and calibrators, crucial for the accuracy of drug-level tests, and witness a growing demand due to their repetitive use. Data management services are pivotal, offering advanced solutions for efficiently handling the extensive data yielded from TDM processes, including software and systems designed for data collection, analysis, and reporting, ensuring streamlined management of crucial patient and treatment information. The equipment segment encompasses various analyzers and detectors, such as chromatography & MS Detectors for specific and sensitive drug detection, clinical chemistry analyzers for broad biochemical testing, and immunoassay analyzers for quick and effective drug quantification.

End-User: Increasing demand from hospitals where accurate drug management is essential

Hospital labs are instrumental in refining patient care, particularly for treatments requiring precise dosing due to the narrow therapeutic index, high toxicity, or individual variations in drug metabolism and action. This approach is essential in acute care scenarios and specialties such as oncology and transplant medicine, where accurate drug management is crucial to patient survival and recovery. Private laboratories cater to a broader outpatient population, collaborating closely with primary care and specialty physicians to manage long-term conditions, including mental health, cardiovascular, and autoimmune diseases. Private laboratories provide timely drug-level assessments and are indispensable in guiding physicians toward making educated decisions on dosage modifications and medication selection, thereby ensuring tailored and efficacious patient treatment plans.

Regional Insights

The therapeutic drug monitoring market shows a highly evolving landscape in the Americas owing to the increasing demand for organ transplantation, usage of precision medicines, and applications of TDM in healthcare areas, including hospital labs and private labs. The rising prevalence of chronic diseases, and increasing consumer switch towards personalized medications, tremendously increase the demand for therapeutic drug monitoring for drug development process in APAC and EMEA regions. European governments have shifted their focus towards launching the Framework Programme for Research and Technological Development, which aims to develop new personalized medicine leading to a rise in investment and funding. Governments worldwide are focusing on accelerating genomic research activities for the development of different types of drugs, and recognizing the clinical benefits of therapeutic drug monitoring is expected to raise demand for TDM from hospitals worldwide for better treatment outcomes with minimum side effects from the medication.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Therapeutic Drug Monitoring Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Therapeutic Drug Monitoring Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Therapeutic Drug Monitoring Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., apDia Group, ARK Diagnostics, Inc., ARUP Laboratories, Assay Genie, Bio-Rad Laboratories, Inc., bioMerieux SA, Buhlmann Laboratories AG, Cambridge Life Sciences Limited, Cardinal Health, Inc., Chromsystems Instruments & Chemicals GmbH, Danaher Corporation, DiaSorin SpA, DiaSystem Scandinavia AB, Eagle Biosciences, Inc., Exagen Inc., F. Hoffmann-La Roche AG, Grifols, S.A., H.U. Group Holdings, Inc., Krishgen Biosystems, Merck KGaA, Myriad Genetics, Inc., Neoteryx, LLC by Trajan Group, OneCare Media, LLC, Pfizer Inc., R-Biopharm AG, Randox Laboratories, Ltd., Sekisui Chemical Co Ltd., Siemens Healthineers AG, Svar Life Science AB, Tecan Trading AG, Theradiag SA, Thermo Fisher Scientific, Inc., and Veolia Group.

Market Segmentation & Coverage

This research report categorizes the Therapeutic Drug Monitoring Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Consumables
- Data Management Services
- Equipment
  - Chromatography & MS Detectors
  - Clinical Chemistry Analyzers
  - Immunoassay Analyzers
Technology
- Chromatography-MS
  - GC-MS
  - LC-MS

Immunoassays
- Chemiluminescence Immunoassays
- Colorimetric Immunoassays
- Fluorescence Immunoassays
- Radioimmunoassays

Proteomic Technologies

Drug Class
- Antiarrhythmic Drugs
- Antibiotic Drugs
- Antiepileptic Drugs
- Bronchodilator Drugs
- Immunosuppressant Drugs
- Psychoactive Drugs

End-User
- Hospital Labs
- Private Labs

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Therapeutic Drug Monitoring Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Therapeutic Drug Monitoring Market?

3. What are the technology trends and regulatory frameworks in the Therapeutic Drug Monitoring Market?

4. What is the market share of the leading vendors in the Therapeutic Drug Monitoring Market?

5. Which modes and strategic moves are suitable for entering the Therapeutic Drug Monitoring Market?

Product Code: MRR-A77F2EE7AB43

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increased Demand for Personalized Medicine
  - 5.1.1.2. Rising Adoption of Therapeutic Drug Monitoring Across Various Therapeutic Fields
  - 5.1.1.3. Growing Use and Importance in Patients with Solid Organ Transplantation
- 5.1.2. Restraints
  - 5.1.2.1. Inadequate Reimbursement Policies
  - 5.1.2.2. Need of High Capital Investments
- 5.1.3. Opportunities
  - 5.1.3.1. Future Perspectives of Therapeutic Drug Monitoring in Developing Nations
  - 5.1.3.2. Developments in Immunoassay and Other Therapeutic Drug Monitoring Technologies
- 5.1.4. Challenges
  - 5.1.4.1. Clinical Challenges and Limited Availability of Skilled Laboratory Technicians
5.2. Market Segmentation Analysis
- 5.2.1. Product: Rising demand for data management services for efficient drug management
- 5.2.2. End-User: Increasing demand from hospitals where accurate drug management is essential
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. Therapeutic Drug Monitoring Market, by Product

6.1. Introduction
6.2. Consumables
6.3. Data Management Services
6.4. Equipment

7. Therapeutic Drug Monitoring Market, by Technology

7.1. Introduction
7.2. Chromatography-MS
7.3. Immunoassays
7.4. Proteomic Technologies

8. Therapeutic Drug Monitoring Market, by Drug Class

8.1. Introduction
8.2. Antiarrhythmic Drugs
8.3. Antibiotic Drugs
8.4. Antiepileptic Drugs
8.5. Bronchodilator Drugs
8.6. Immunosuppressant Drugs
8.7. Psychoactive Drugs

9. Therapeutic Drug Monitoring Market, by End-User

9.1. Introduction
9.2. Hospital Labs
9.3. Private Labs

10. Americas Therapeutic Drug Monitoring Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Therapeutic Drug Monitoring Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Therapeutic Drug Monitoring Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Capitainer announces collaboration with AstraZeneca.
- 13.3.2. Novo Holdings invests in proteomics technology company, Evosep.
- 13.3.3. AegirBio AB enters into an agreement with Atlas Special Opportunities, LLC regarding convertible bonds of SEK 55 million with attached warrants to intensify investments in i.a. TDM and saliva sampling.
- 13.3.4. Clinical LC-MS methods for therapeutic drug monitoring analysis.
- 13.3.5. Boditech Med has obtained the export license of four TDM products.
- 13.3.6. Pace Obtains EPA Approval on Method for Detecting Dioxins and Dibenzofurans Through GC-MS/MS Technology.
- 13.3.7. Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Bioanalysis and Drug Monitoring.
- 13.3.8. Beckman Coulter and Saladax Biomedical Team Up on Antipsychotic Therapeutic Drug Monitoring.
- 13.3.9. Ampersand Capital Partners Invests in Syft Technologies, Leading SIFT-MS Solutions Provider.

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio